Paliperidone Palmitate 3-Month Formulation
Molecular Mechanisms of Pharmacological Action
Luye Pharma Group Ltd.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Molecular Mechanisms of Pharmacological Action cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Guanfacine Maimonides Medical Center | Phase 4 | BB |
Empagliflozin Yonsei University | Phase 4 | BB |
Pioglitazone Yonsei University | Phase 4 | BB |
SACUBITRIL VALSARTAN Silesian Centre for Heart Diseases | Phase 4 | BB |
Sorafenib Sichuan Cancer Hospital and Research Institute | Phase 2 | B |
View all 15 →
Same molecule, other indications
Paliperidone Palmitate 3-Month Formulation is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →